Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

NCT07804615 is registered in ClinicalTrials.gov with Vima Therapeutics as lead sponsor.

NCT NCT07804615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07804615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Lead sponsor
Vima Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2027
Enrollment
80 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease (disorder)